PRNewsWire
15 Jun 2026, 06:34 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The lawsuit claims Immutep knew the TACTI-004 trial would fail to meet primary efficacy endpoints while publicly stating it was showing 'strong operational progress.' — Direct allegations of clinical trial failure for a lead asset are highly material for biotech valuations.
-0.80Immutep Limited is facing a class action lawsuit alleging it made false and misleading statements regarding the TACTI-004 trial of eftilagimod alfa. — Securities litigation alleging fraud regarding a core clinical trial typically triggers investor sell-offs and increases regulatory risk.
-0.60Which stocks this story touches
The company is mentioned as being sued for securities law violations.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action lawsuit alleging false and misleading statements regarding clinical trial results.
The company is mentioned as being sued for securities law violations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
